Information and Support for ADSTILADRIN

Download practice resources

ADSTILADRIN Clinical Overview Downloadable Guide

ADSTILADRIN Clinical Overview

A clinical resource highlighting key information about ADSTILADRIN (nadofaragene firadenovec-vncg)

ADSTILADRIN Instructions for Use Downloadable Guide

Instructions for Use

A summary of storage, preparation, administration, and disposal information for ADSTILADRIN

How to Order ADSTILADRIN Leave Behind Downloadable Guide


A step-by-step guide on how to order ADSTILADRIN, including product codes

ADSTILADRIN Patient Enrollment Form Downloadable Guide

Patient Enrollment Form

Once you have identified your patient for ADSTILADRIN, please use this enrollment form to begin the ordering process

Submit your enrollment form at

Replacement Policy

ADSTILADRIN Product Replacement Policy

A document that outlines the procedure for returning ADSTILADRIN product, including eligibility criteria and requirements

Download patient materials

Getting Started With ADSTILADRIN for Patients

A patient-friendly overview of the ADSTILADRIN clinical story as well as what patients should expect before and after treatment

Download reimbursement resources

Medicare Part B Reimbursement Downloadable Guide

Medicare Part B Reimbursement Guide

Information about Medicare Part B reimbursement

ADSTILADRIN Copay Program Leave Behind Downloadable Guide

ADSTILADRIN Copay Program Leave Behind

An overview of the ADSTILADRIN Copay Program. Eligible, commercially insured patients may pay as little as $100* for each ADSTILADRIN prescription

Verify eligibility

ADSTILADRIN Pass-Through Leave Behind

A quick summary of the pass-through status for ADSTILADRIN, including coding details

ADSTILADRIN Average Sales Price (ASP) Leave Behind

A leave behind that outlines the establishment of the ASP for ADSTILADRIN

Watch videos


Neal Shore, MD, FACS, discusses key information about ADSTILADRIN treatment, including preparation and administration

Watch Now

Hear From a Board-Certified Urologist

Lawrence Karsh, MD, FACS, shares his experience from the ADSTILADRIN clinical trials

Watch Now
ADSTILADRIN® (nadofaragene firadenovec-vncg) Mechanism of Action video thumbnail

ADSTILADRIN Is a Localized Treatment for Localized Tumors

Watch the mechanism of action video to learn more about how ADSTILADRIN works

Watch Now

*Available only for patients who meet eligibility requirements. Program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.

Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)

Form Toggle

Your Information

Your Mailing Address

*Required field.

Important Safety Information


ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.


CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.


  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?

Latest Updates


Effective April 1, 2024, ADSTILADRIN has established an average sales price (ASP) in accordance with the guidelines set forth by the Centers for Medicare & Medicaid Services Part B. This determination is a significant milestone for Ferring Uro-Oncology and represents our commitment to providing transparency and value to our customers.

To get ongoing updates about ADSTILADRIN, please sign up here.